
TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings
TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于2023年前三季度计提资产减值准备的公告 | 2023-10-30 | Chinese | |
| 关于公司2023年度对外担保预计的进展公告 | 2023-10-24 | Chinese | |
| 关于2022年股票期权激励计划首次授予股票期权第一个行权期限制行权期间的提示性公告 | 2023-10-16 | Chinese | |
| 关于2022年股票期权激励计划2023年第三季度自主行权结果暨股份变动的公告 | 2023-10-09 | Chinese | |
| 关于公司2023年度对外担保预计的进展公告 | 2023-10-09 | Chinese | |
| 关于公司2023年度对外担保预计的进展公告 | 2023-09-27 | Chinese |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 38190292 | 关于2023年前三季度计提资产减值准备的公告 | 2023-10-30 | Chinese | ||
| 38190269 | 关于公司2023年度对外担保预计的进展公告 | 2023-10-24 | Chinese | ||
| 38190252 | 关于2022年股票期权激励计划首次授予股票期权第一个行权期限制行权期间的提示性公告 | 2023-10-16 | Chinese | ||
| 38190236 | 关于2022年股票期权激励计划2023年第三季度自主行权结果暨股份变动的公告 | 2023-10-09 | Chinese | ||
| 38190221 | 关于公司2023年度对外担保预计的进展公告 | 2023-10-09 | Chinese | ||
| 38190209 | 关于公司2023年度对外担保预计的进展公告 | 2023-09-27 | Chinese | ||
| 38190191 | 关于公司提起诉讼的公告 | 2023-09-19 | Chinese | ||
| 38190178 | 关于变更保荐代表人的公告 | 2023-09-18 | Chinese | ||
| 38190167 | 关于公司2023年度对外担保预计的进展公告 | 2023-09-18 | Chinese | ||
| 38190152 | 独立董事关于第四届董事会第十八次会议相关议案的独立意见 | 2023-09-14 | Chinese | ||
| 38190139 | 关于部分募投项目延期的公告 | 2023-09-14 | Chinese | ||
| 38190128 | 中德证券有限责任公司关于天域生态环境股份有限公司募投项目延期的核查意见 | 2023-09-14 | Chinese | ||
| 38190107 | 关于向特定对象发行股票募集说明书等申请文件更新财务数据的提示性公告 | 2023-09-12 | Chinese | ||
| 38190092 | 天域生态环境股份有限公司向特定对象发行A股股票募集说明书(注册稿)(2023年半年度财务数据更新版) | 2023-09-12 | Chinese | ||
| 38189956 | 众华会计师事务所(特殊普通合伙)关于天域生态环境股份有限公司向特定对象发行A股股票的财务报告及审计报告及最近一期的财务报告 | 2023-09-12 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
TIANYU BIO-TECHNOLOGY CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/57798/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=57798 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=57798 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=57798 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 57798}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for TIANYU BIO-TECHNOLOGY CO.,LTD. (id: 57798)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.